HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy.

AbstractPURPOSE:
The purpose of this study was to evaluate the initial and day 4 beta-human chorionic gonadotropin (β-hCG) levels as a predictor of methotrexate (MTX) therapy success for ectopic pregnancy.
METHODS:
Retrospective study of 87 patients with tubal ectopic pregnancy treated with a single dose of 50 mg/m(2) MTX at Bursa Şevket Yılmaz Research and Education Hospital between January 2011 and July 2012 was performed.
RESULTS:
The overall success rate is measured as 72.4 %. The two groups of patients, successfully treated patients (n = 63) and unsuccessfully treated patients (n = 24), were compared. The mean initial β-hCG level was significantly lower in the treatment success group than in the treatment failure group (1,417 mIU/mL versus 5,995 mIU/mL, p < 0.001). The number of cases with decreasing β-hCG level on day 4 was significantly more in the success group compared to the failure group (61.9 and 37.5 %, respectively, p = 0.04). The success rate was 90 % when β-hCG levels were <1,000 mIU/mL, 85.7 % when the levels were between 1,000 and 1,999 mIU/mL, and 76.5 % when the levels were between 2,000 and 2,999 mIU/mL, 54.5 % when the levels were between 3,000 and 3,999 mIU/mL.
CONCLUSION:
Single-dose MTX therapy is a safe and effective treatment modality for tubal ectopic pregnancies with the β-hCG serum concentration below 3,000 mIU/mL, and β-hCG level changes between days 0 and 4 after MTX therapy are important in predicting the outcome of treatment.
AuthorsEmın Ustunyurt, Muzeyyen Duran, Esra Coskun, Özlem Basak Ustunyurt, Harun Simşek
JournalArchives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 288 Issue 5 Pg. 1149-52 (Nov 2013) ISSN: 1432-0711 [Electronic] Germany
PMID23666603 (Publication Type: Journal Article)
Chemical References
  • Abortifacient Agents, Nonsteroidal
  • Chorionic Gonadotropin, beta Subunit, Human
  • Methotrexate
Topics
  • Abortifacient Agents, Nonsteroidal (therapeutic use)
  • Adult
  • Chorionic Gonadotropin, beta Subunit, Human (blood)
  • Female
  • Humans
  • Methotrexate (therapeutic use)
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy, Tubal (blood, drug therapy)
  • Retrospective Studies
  • Time Factors
  • Treatment Failure
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: